Mirum Pharmaceuticals Expands Rare Liver Portfolio Through Bluejay Strategic Takeover

Mirum Pharmaceuticals (MIRM) unveiled a significant strategic move in the rare liver disease sector, revealing plans to acquire Bluejay Therapeutics for approximately $620 million through a combined cash and stock transaction. This acquisition marks a notable expansion of Mirum’s therapeutic capabilities in treating rare hepatic conditions.

The cornerstone of this deal centers on Brelovitug, an advanced-stage monoclonal antibody candidate designed to address chronic hepatitis delta virus. The compound carries prestigious designations, including Breakthrough Therapy and PRIME status from regulatory authorities. Currently advancing through the global AZURE Phase 3 trial, Brelovitug is positioned to deliver top-line efficacy and safety data by late 2026.

For Mirum, this integration translates into meaningful clinical momentum. The company projects achieving as many as four potential registrational milestones across its rare liver portfolio within the next 18 months. This acceleration reflects the strategic importance of expanding treatment options for underserved hepatic disorders, from established conditions like liver paste complications to emerging viral hepatitis variants.

Supporting this ambitious agenda, Mirum launched a concurrent $200 million private placement financing initiative. These capital infusions are earmarked for advancing development timelines and establishing robust commercialization infrastructure for newly acquired assets.

Transaction closure is anticipated during early 2026. Market participants noted that MIRM shares traded at $68.01 on the Nasdaq, reflecting modest movement of $0.47 or 0.69 percent at the time of announcement, suggesting measured investor positioning around the strategic news.